Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II crossover trial of oral PHA-022121 for acute hereditary angioedema attacks
NL-OMON55154Phase 2Active, not recruiting
- Sponsor
- Pharvaris
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucrictibant in hereditary angioedema (HAE) (4 arms), sponsored by Pharvaris. Primary endpoint: Change of VAS-3 score during acute attacks. Started May 2021; status: active, not recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON55154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55154.